People: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

59.38USD
22 May 2015
Change (% chg)

$-0.72 (-1.20%)
Prev Close
$60.10
Open
$59.96
Day's High
$60.00
Day's Low
$59.34
Volume
2,572,564
Avg. Vol
3,081,292
52-wk High
$63.62
52-wk Low
$52.49

Search Stocks

Summary

Name Age Since Current Position

Kenneth Frazier

60 2011 Chairman of the Board, President, Chief Executive Officer

Robert Davis

48 2014 Chief Financial Officer, Executive Vice President

Clark Golestani

48 2012 Executive Vice President, Chief Information Officer

Michael Holston

52 2012 Executive Vice President, Chief Ethics and Compliance Officer

Bruce Kuhlik

58 2009 Executive Vice President, General Counsel

Mirian Graddick-Weir

60 2009 Executive Vice President - Human Resources

Willie Deese

59 2009 Executive Vice President, President - Merck Manufacturing Division

Richard DeLuca

52 2011 Executive Vice President, President - Merck Animal Health

Julie Gerberding

59 2015 Executive Vice President - Strategic Communications, Global Public Policy & Population Health

Roger Perlmutter

63 2013 Executive Vice President, President - Merck Research Laboratories

Michael Rosenblatt

67 2009 Executive Vice President, Chief Medical Officer

Adam Schechter

50 2010 Executive Vice President, President - Global Human Health

Rita Karachun

51 2014 Senior Vice President - Finance, Global Controller

Adele Ambrose

58 2009 Senior Vice President, Chief Communications Officer

William Harrison

71 2009 Lead Independent Director

Leslie Brun

62 2008 Independent Director

Thomas Cech

68 2009 Independent Director

Thomas Glocer

55 2007 Independent Director

C. Robert Kidder

70 2005 Independent Director

Rochelle Lazarus

67 2004 Independent Director

Carlos Represas

70 2009 Independent Director

Patricia Russo

62 1995 Independent Director

Craig Thompson

62 2008 Independent Director

Wendell Weeks

55 2004 Independent Director

Peter Wendell

64 2003 Independent Director

Joseph Romanelli

2015 IR Contact Officer

Biographies

Name Description

Kenneth Frazier

Mr. Kenneth C. Frazier is Chairman of the Board, President, Chief Executive Officer of Merck & Co., Inc. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company (2009 to 2010) and Merck Sharp & Dohme Corp. (2007 to 2009). Mr. Frazier also served as Executive Vice President and General Counsel (2006 to 2007) of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.). Director, Exxon Mobil Corporation since 2009 and Pharmaceutical Research and Manufacturers of America (PhRMA) since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association.

Robert Davis

Mr. Robert M. Davis is Chief Financial Officer, Executive Vice President of Merck & Co., Inc., since April 23, 2014. Mr. Davis is responsible for the Company’s global financial organization, investor relations, corporate strategy and business development, global facilities, and the Company’s joint venture relationships. Prior to starting his employment with the Company, Mr. Davis served as Corporate Vice President and President, Medical Products of Baxter International, Inc. (“Baxter”), a healthcare company, a position he had held since October 2010. In that position, Mr. Davis was responsible for all aspects of commercial, R&D, quality, regulatory, manufacturing and supply chain functions. Prior to that position, Mr. Davis served as Corporate Vice President and President, Renal Division of Baxter in 2010 and had previously served as Baxter’s Corporate Vice President and Chief Financial Officer from 2006 to 2010.

Clark Golestani

Mr. Clark Golestani is Executive Vice President, Chief Information Officer of Merck & Co., Inc. He is responsible for Merck’s global information technology (IT). His experience includes August 2008 — Vice President, Merck Research Laboratories Information Technology, Merck & Co., Inc. — responsible for global IT for Merck’s Research & Development division, including Basic Research, PreClinical, Clinical and Regulatory & from November 2006 — Vice President, Corporate Information Technology, Merck & Co., Inc. — responsible for global IT supporting Finance, Human Resources, Procurement, Legal, Public Affairs, Site Services, Real Estate, and Shared Business Services operations.

Michael Holston

Mr. Michael J. Holston is Executive Vice President, Chief Ethics and Compliance Officer, General Counsel of Merck & Co Inc. with effect from July 1, 2015. Mr. Holston most recently served as executive vice president and general counsel for Hewlett-Packard Company, where he oversaw compliance, government affairs, privacy, ethics operations and legal affairs. Prior to his role with Hewlett-Packard, Holston was a partner in the litigation practice at Morgan, Lewis & Bockius LLP, where he served as external counsel to Merck on matters such as product litigation, government investigations and compliance with healthcare laws and regulations. Before joining Morgan Lewis, he served as a prosecutor in the criminal division of the U.S. Attorney's Office for the Eastern District of Pennsylvania. Holston received his J.D. from Villanova University School of Law, Villanova, Penn. and a B.S.M.E. from the University of Notre Dame, South Bend, Indiana. He also is a fellow in the American College of Trial Lawyers.

Bruce Kuhlik

Mr. Bruce N. Kuhlik is Executive Vice President of Merck & Co., Inc., since July 1, 2015. He is responsible for the Company’s legal function. From January 2008 to November 2009 — Executive Vice President and General Counsel, Merck & Co., Inc. — responsible for legal, communications, and public policy functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company). From August 2007 to January 2008 — Senior Vice President and General Counsel, Merck & Co., Inc. — responsible for legal, communications, and public policy functions and The Merck Company Foundation (a not-for-profit charitable organization affiliated with the Company). since May 2005 — Vice President and Associate General Counsel, Merck & Co., Inc. — primary responsibility for the Company’s Vioxx litigation defense.

Mirian Graddick-Weir

Dr. Mirian M. Graddick-Weir is Executive Vice President - Human Resources of Merck & Co., Inc. She is responsible for the Global Human Resources organization. Since January 2008 — Executive Vice President, Human Resources, Merck & Co., Inc. — responsible for the Global Human Resources organization. Since September 2006 — Senior Vice President, Human Resources, Merck & Co., Inc.

Willie Deese

Mr. Willie A. Deese is Executive Vice President, President - Merck Manufacturing Division of Merck & Co., Inc. He is responsible for the Company’s global manufacturing, procurement, and distribution and logistics functions. Since January 2008 — Executive Vice President and President, Merck Manufacturing Division, Merck & Co., Inc. — responsible for the Company’s global manufacturing, procurement, and distribution and logistics functions. Since May 2005 — President, Merck Manufacturing Division, Merck & Co., Inc. — responsible for the Company’s global manufacturing, procurement, and operational excellence functions.

Richard DeLuca

Mr. Richard R. DeLuca, Jr., is Executive Vice President, President - Merck Animal Health of Merck & Co Inc. He is responsible for the Merck Animal Health organization. Prior to September 2011, Mr. DeLuca was Chief Financial Officer, Becton Dickinson Biosciences (a medical technology company) since 2010 and President, Wyeth’s Fort Dodge Animal Health division from 2007 to 2010. He served as Chief Operating Officer, Fort Dodge from 2006 to 2007 and Executive Vice President and Chief Financial Officer from 2002 to 2006.

Julie Gerberding

Dr. Julie Louise Gerberding is Executive Vice President - Strategic Communications, Global Public Policy and Population Health of Merck & Co., Inc. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck’s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck’s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Merck’s vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Merck’s European vaccine business for which Gerberding is the Board co-chair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust non-profit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories. Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention (CDC) from 2002-2009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF.

Roger Perlmutter

Dr. Roger M. Perlmutter, M.D., Ph.D., is Executive Vice President, President - Merck Research Laboratories of Merck & Co Inc. effective April 15, 2013. He is responsible for the Company’s global research and development efforts. Dr. Perlmutter was executive vice president and head of R&D at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.

Michael Rosenblatt

Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck & Co., Inc. He is responsible for the Company’s primary voice to the global medical community on critical issues such as patient safety and oversight for the Company’s Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003.

Adam Schechter

Mr. Adam H. Schechter is Executive Vice President, President - Global Human Health of Merck & Co., Inc. He is responsible for the Company’s global pharmaceutical and vaccine business. Since November 2009 — President, Global Human Health, U.S. Market-Integration Leader, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Leader for the integration efforts for the Merck/Schering-Plough merger across all divisions and functions. Since August 2007 — President, Global Pharmaceuticals, Global Human Health, Merck & Co., Inc. — global responsibilities for the Company’s atherosclerosis/cardiovascular, diabetes/obesity, oncology, specialty/neuroscience, respiratory, bone, arthritis and analgesia franchises as well as commercial responsibility in the United States for the Company’s portfolio of prescription medicines. Since July 2006 — President, U.S. Human Health, Merck & Co., Inc. — commercial responsibility in the United States for the Company’s portfolio of prescription medicines.

Rita Karachun

Ms. Rita A. Karachun is Senior Vice President - Finance, Global Controller of Merck & Co., Inc., since March 1, 2014. She is responsible for the Company’s global controller’s organization including all accounting, controls, external reporting and financial standards and policies. She has served as Assistant Controller of the Company since November 2009. Prior to her appointment as Assistant Controller of the Company, Ms. Karachun served as the Assistant Controller of Schering-Plough Corporation since February 2007 and was responsible for preparing financial statements and for the worldwide consolidation of international entities.

Adele Ambrose

Ms. Adele D. Ambrose is Senior Vice President, Chief Communications Officer of Merck & Co., Inc. She is responsible for the Global Communications organization. Since December 2007 — Vice President and Chief Communications Officer, Old Merck — responsible for the Global Communications organization.

William Harrison

Mr. William B. Harrison Jr., is Lead Independent Director of Merck & Co Inc. He is Retired Chairman of the Board, JPMorgan Chase & Co., since 2007, prior to which he was Chairman beginning in 2000 and Chief Executive Officer from 1999 until 2006. Chairman, Cadence Bancorp LLC (formerly Community Bancorp LLC) since 2010 (bank holding company); Director, Aurora Capital Group since 2007 (private equity firm), Lincoln Center for the Performing Arts since 2006, RecoverCare LLC since 2009 (healthcare company) and The University of North Carolina Endowment Fund; Member, Board of Overseers of Memorial Sloan-Kettering Cancer Center and the National September 11 Memorial Museum Foundation. Mr. Harrison was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 1999 to 2009 and Cousins Properties Incorporated (diversified development company) from 2006 to 2012.

Leslie Brun

Mr. Leslie A. Brun is Independent Director of Merck & Co., Inc . He is Chairman and Chief Executive Officer, Sarr Group, LLC since 2006 and Managing Director and Head of Investor Relations, CCMP Capital (global private equity firm) since 2011; Chairman Emeritus of Hamilton Lane since 2006, prior to which he served as Chief Executive Officer and Chairman from 1991 until 2005. Non-Executive Chairman of the Board, Automatic Data Processing, Inc., since 2007 and Director since 2003 (global provider of business outsourcing solutions) and Non-Executive Chairman of the Board, Broadridge Financial Solutions, Inc. since 2011 and Director since 2007 (investor communications and business process outsourcing provider); Director, NXT Capital, Inc. (a private specialty financing company); Member, Council on Foreign Relations. Mr. Brun was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2008 to 2009.

Thomas Cech

Dr. Thomas R. Cech Ph.D., is Independent Director of Merck & Co., Inc. He has been Investigator, Howard Hughes Medical Institute since 1988, and President from 2000 to 2009; Faculty, University of Colorado since 1978; Director, BioFrontiers Institute, University of Colorado since 2009. Trustee, Grinnell College; Member, National Academy of Sciences. Dr. Cech was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from May to November 2009.

Thomas Glocer

Mr. Thomas H. Glocer is Independent Director of Merck & Co Inc. He Retired Chief Executive Officer, Thomson Reuters Corporation since December 2011, prior to which he was Chief Executive Officer of Thomson Reuters from 2008 and Chief Executive Officer of its predecessor, Reuters Group PLC, from 2001. Founder and Managing Partner, Angelic Ventures, L.P; Director, Council on Foreign Relations; nominated Director, Morgan Stanley; Member, Board of Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitors, and President’s Council on International Activities at Yale University. Mr. Glocer was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2007 to 2009, Reuters Group PLC from 2000 to 2008 and Thomson Reuters Corporation from 2008 to 2011.

C. Robert Kidder

Mr. C. Robert Kidder is Independent Director of Merck & Co., Inc. Mr. Kidder was Chairman of the Board of Directors, Chrysler Group LLC from 2009 to 2011. Mr. Kidder also served as Chairman and Chief Executive Officer of 3Stone Advisors LLC from 2006 to 2011 and was a Principal of Stonehenge Partners, Inc. from 2004 to 2006. Director, Morgan Stanley since 1994 (investment bank), Microvi Biotech Inc. since 2008 (water filtration company) and Wildcat Discovery Technologies, Inc. since 2012 (private technology research company); Board of Trustees, Nationwide Children’s Hospital (Columbus) since 1998 and Wexner Center for the Arts Foundation since 1999.

Rochelle Lazarus

Ms. Rochelle B. Lazarus is Independent Director of Merck & Co., Inc. She is Chairman Emeritus, Ogilvy & Mather, since 2012. Ms. Lazarus was Chairman, Ogilvy & Mather Worldwide from 2008 to 2012 and Chairman and Chief Executive Officer from 1996 to 2008. Director, General Electric since 2000 (diversified technology, media and financial services company), Partnership for New York City and World Wildlife Fund. Trustee, New York Presbyterian Hospital since 1995, American Museum of Natural History since 2003 and Lincoln Center for the Performing Arts. Member, Board of Overseers of Columbia Business School since 1993, The Business Council, Council on Foreign Relations, and President’s Council on International Activities at Yale University. Ms. Lazarus was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2004 to 2009.

Carlos Represas

Mr. Carlos Eduardo Represas is Independent Director of Merck & Co., Inc. He is Retired Executive Vice President—Head of the Americas, Nestlé, S.A., Switzerland, from 1994 to 2004. Retired Chairman, Nestlé Group Mexico, since 2011, prior to which he served as Chairman since 1983. Non-Executive Chairman, Bombardier Latin America since 2011. Director, Bombardier Inc. since 2004 (aerospace & transportation company), Swiss Re Group and Swiss Re America Holding Corporation since 2010 (reinsurance and insurance companies); Board Member, Mexican Health Foundation since 1985 (not-for-profit private organization); Trustee, National Institute of Genomic Medicine, Ministry of Health, Mexico since 2004; Member, Latin America Business Council and the Dean’s Advisory Board, Harvard School of Public Health. Mr. Represas was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from February to November 2009 and served on the board of Vitro S.A.B. de C.V. from 1998 to 2008 (glass manufacturing company).

Patricia Russo

Ms. Patricia F. Russo is Independent Director of Merck & Co. Inc. She is Lead Director, General Motors Company since 2010 and Director since 2009 (auto manufacturer); Director, Alcoa Inc. since 2008 (producer and manager of aluminum) and Hewlett-Packard Company since 2011 (a technology company). Ms. Russo was Chief Executive Officer and Director, Alcatel-Lucent from 2006 through 2008. She previously served as Chairman of Lucent Technologies Inc. from 2003 to 2006 and Chief Executive Officer and President from 2002 to 2006. Chairman, Partnership For a Drug-Free America since 2010; Member, The Business Council, The Economic Club of New York and The Conference Board.

Craig Thompson

Dr. Craig B. Thompson, M.D., is an Independent Director of Merck & Co. Inc. He is President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center since 2010. Dr. Thompson was Professor of Medicine at the University of Pennsylvania School of Medicine from 1999 to 2011 and Director of the Abramson Cancer Center from 2006 to 2010. Fellow, American Academy of Arts and Sciences; Member, Medical Advisory Board of the Howard Hughes Medical Institute and The National Academy of Sciences and its Institute of Medicine.

Wendell Weeks

Mr. Wendell P. Weeks is Independent Director of Merck & Co., Inc. He is President since 2010 and Chairman and Chief Executive Officer, Corning Incorporated, since 2007, prior to which he was President and Chief Executive Officer from 2005 to 2007, and President and Chief Operating Officer from 2002 to 2005. Director, Corning Incorporated since 2000. Mr. Weeks was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2004 to 2009.

Peter Wendell

Mr. Peter C. Wendell is Independent Director of Merck & Co., Inc. He is Managing Director, Sierra Ventures since 1982; Faculty, Stanford University Graduate School of Business since 1991. Senior Advisor and Director, WestBridge Crossover Fund, LLC since 2011; Charter Trustee, Princeton University; Chairman, Princeton University Investment Co. from 2003 to 2008 and Director from 1998 to 2008. Mr. Wendell was also a director of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.) from 2003 to 2009.

Joseph Romanelli

Search Stocks